NCT00097214View on ClinicalTrials.gov

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Carboplatin

AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.

BIOLOGICAL

Cetuximab

400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.

Trial Locations (8)

19047

ImClone Investigational Site, Langhorne

19104

ImClone Investigational Site, Philadelphia

27599

ImClone Investigational Site, Chapel Hill

28309

ImClone Investigational Site, Fayetteville

30084

ImClone Investigational Site, Tucker

40202

ImClone Investigational Site, Louisville

60201

ImClone Investigational Site, Evanston

72712

ImClone Investigational Site, Bentonville

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT00097214 - Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter